Third dose of AstraZeneca's Vaxzevria increases antibody response against Omicron variant
Dan Kitwood/Getty Images News


Positive results from a preliminary analysis of an ongoing trial showed that AstraZeneca's (NASDAQ:AZN) Vaxzevria (ChAdOx1-S [Recombinant]), when given as a third dose booster, increased the immune response to Beta, Delta, Alpha and Gamma SARS-CoV-2 variants.
Also, a separate analysis of samples from the trial showed increased antibody response to the Omicron variant.
The increased response was seen in individuals previously vaccinated with either Vaxzevria or an mRNA vaccine.
The Company is submitting these additional data to health authorities around the world given the urgent need for boosters.
The trial showed that Vaxzevria continued to be generally well tolerated. Further analyses are expected in H1 2022.
Previous studies have also supported Vaxzevria as a third dose booster as part of a homologous or heterologous schedule.
Last month, lab studies had shown that a three-dose course of Vaxzevria boosted antibody levels against Omicron variant.